Drug dependence: Towards a new treatment?

July 21, 1999

New perspectives for treating drug dependence are opening up thanks to work by Pierre Sokoloff's team at INSERM 109 (director Jean-Charles Schwartz), in collaboration with CNRS, Cambridge University and the French pharmaceutical company Bioprojet. A new compound has proved capable of reducing drug seeking in cocaine-dependent rats. This compound, the first specific activator of the D3 dopamine receptor, might help addicts to attenuate their frantic drug-seeking behavior and to reduce the risk of relapse after withdrawal. The effect might extend beyond cocaine to other forms of dependence. These results - the fruit of 10 years' work - have just been published in Nature.

How to overcome dependence on drugs or smoking? Until now only substitution treatments - methadone, SubutexR or nicotine patches - are available. These treatments have limited efficacy and do not tackle the heart of the problem, i.e. craving and compulsive drug-seeking.

For the last 10 years the team led by Pierre Sokoloff at INSERM unit 109 have been examining an original way of inhibiting the drug craving associated with environmental images or signals. It is well established that a person's environment at the time of drug-taking is of capital importance: as the person becomes addicted, he or she gradually links the use of the product to particular signals or images, such as the sight of a spoon, a syringe or a particular atmosphere. Simply encountering these signals can trigger craving and drug-seeking behavior. Many relapses, even years after withdrawal, are due to images evoking the drug.

The story began in 1989 when P. Sokoloff, J.C. Schwartz and coworkers discovered the third receptor for the neurotransmitter dopamine, called the D3 receptor. This receptor is located in a restricted area of the brain, the nucleus acumbens, the key region of dependence: all products that induce dependence in humans, be it cocaine, morphine, heroin, nicotine or alcohol, increase dopamine release in this area. Genetic, pharmacological and physiological evidence argues for the involvement of the D3 receptor in drug dependence.

The idea was forwarded to develop a drug capable of modulating the activity of the receptor and thereby to treat the dependence. The compound would have to specifically bind to the D3 receptor and partially activate it. Thanks to collaboration with the team headed by Camille G. Wermuth (CNRS ERS 655, Illkirch) and scientists from Bioprojet laboratories (Paris), several hundred compounds were synthesized and analyzed. BP 897 successfully passed the battery of in vitro and in vivo tests, and is the first specific and partial D3 receptor agonist to be developed.

BP 897 was then tested by Barry J. Everitt at Cambridge University on cocaine-dependent rats trained to self-administer the drug by pressing a lever. The rats were conditioned to respond to a signal (a light came on at each drug intake). The simple sight of the light, in the absence of available drug, maintained the self-administration behavior (pressing the lever) and even rekindled this behavior after a period of quiescence. This model therefore resembles what happens when people take drugs, as signals or images associated with drug intake suffice to generate an irrepressible desire and to trigger relapse after withdrawal. Thus, the rat's behavior in response to the light signal reasonably reflects frantic drug-seeking and serves as a measure of drug desire and requirements.

Administration of low doses of BP 897 to these dependent rats clearly attenuated their compulsive drug-seeking behavior in response to the light signal. Their cocaine requirements were reduced. BP 897 itself does not act as a drug. Contrary to replacement products, BP 897 does not induce a new type of dependence, and rats do not attempt to self-inject BP 897 when given the possibility.

The implications of this work go beyond cocaine dependence. Indeed, as the D3 receptor is located in the key region for all forms of dependence, BP 897 might conceivably be used for other addictions, to heroin or nicotine for example.

BP 897 is the subject of a joint patent application by INSERM and the French company Bioprojet, which is currently developing the compound as drug. Toxicology results are satisfactory and human trials should start soon.
-end-
For further information

Source
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist
M. Pilla(1), S. Perachon(2)(3), F. Sautel(2), F. Garrido(4), A. Mann(4), C.G. Wermuth(4), J.C. Schwartz(2), B.J. Everitt(1) & P. Sokoloff(2)

(1)University of Cambridge, United Kingdom
(2)U109 INSERM, Paris
(3)Laboratoire Bioprojet, Paris
(4)CNRS ERS 655, Illkirch



French National Institute for Health and Medical Research (INSERM)

Related Cocaine Articles from Brightsurf:

Sleep-deprived mice find cocaine more rewarding
Sleep deprivation may pave the way to cocaine addiction. Too-little sleep can increase the rewarding properties of cocaine, according to new research in mice published in eNeuro.

Nucleus accumbens recruited by cocaine, sugar are different
In a study using genetically modified mice, a University of Wyoming faculty member found that the nucleus accumbens recruited by cocaine use are largely distinct from nucleus accumbens recruited by sucrose, or table sugar.

Astrocytes build synapses after cocaine use in mice
Drugs of abuse, like cocaine, are so addictive due in part to their cellular interaction, creating strong cellular memories in the brain that promote compulsive behaviors.

Of all professions, construction workers most likely to use opioids and cocaine
Construction workers are more likely to use drugs than workers in other professions, finds a study by the Center for Drug Use and HIV/HCV Research (CDUHR) at NYU College of Global Public Health.

Chronic cocaine use modifies gene expression
Chronic cocaine use changes gene expression in the hippocampus, according to research in mice recently published in JNeurosci.

Blocking dopamine weakens effects of cocaine
Blocking dopamine receptors in different regions of the amygdala reduces drug seeking and taking behavior with varying longevity, according to research in rats published in eNeuro.

Born to run: just not on cocaine
A study finds a surprising response to cocaine in a novel strain of mutant mice -- they failed to show hyperactivity seen in normal mice when given cocaine and didn't run around.

Cocaine adulterant may cause brain damage
People who regularly take cocaine cut with the animal anti-worming agent levamisole demonstrate impaired cognitive performance and a thinned prefrontal cortex.

Setting affects pleasure of heroin and cocaine
Drug users show substance-specific differences in the rewarding effects of heroin versus cocaine depending on where they use the drugs, according to a study published in JNeurosci.

One in 10 people have traces of cocaine or heroin on their fingerprints
Scientists have found that drugs are now so prevalent that 13 percent of those taking part in a test were found to have traces of class A drugs on their fingerprints -- despite never using them.

Read More: Cocaine News and Cocaine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.